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Summary
In vivo T cell depletion with 100 mg alemtuzumab prevents graft-versus-
host disease (GVHD) in reduced intensity conditioned transplants but is
associated with delayed immune reconstitution, a higher risk of infection
and relapse. De-escalation studies have shown that a reduced dose of 30 mg
is as effective as 100 mg in preventing GVHD in matched related donor
(MRD) transplants. Dose reduction in matched unrelated donor (MUD)
transplants is feasible but the comparative efficacy of alemtuzumab in this
setting is not known and opinions vary widely concerning the optimal level
of GVHD prophylaxis that should be achieved. Through retrospective analy-
sis we made an objective comparison of MUD transplants receiving an
empirically reduced dose of 60 mg, with MRD transplants receiving a
30 mg dose. We observed proportionate levels of alemtuzumab according to
dose but an inverse relationship with body surface area particularly in MRD
transplants. MUD transplants experienced more acute and chronic GVHD,
higher T cell chimerism, more sustained use of ciclosporin and less need for
donor lymphocyte infusion than MRD transplants. Thus, doubling the dose
of alemtuzumab to 60 mg did not provide equivalent prevention of GVHD
after MUD transplant although there was no difference in non-relapse
mortality or survival compared with MRD transplants.
Keywords: bone marrow transplantation, T cell depletion, graft-versus-host
disease.
Alemtuzumab (CAMPATH 1H), a humanised immunoglob-
ulin G1 (IgG1) monoclonal antibody against CD52, is a well-
established agent for effecting in vivo T cell depletion in the
setting of allogeneic haematopoietic stem cell transplantation.
By reducing the number of both donor and recipient T cells,
it allows engraftment, while reducing the incidence of acute
and chronic graft-versus-host disease (GVHD) (Kottaridis
et al, 2000; Chakraverty et al, 2002). Conventional ale-
mtuzumab dosing (100 mg in five daily doses of 20 mg) has
been shown to ablate acute and chronic GVHD almost com-
pletely in fludarabine and melphalan (FM) conditioned
matched related donor (MRD) and matched unrelated donor
(MUD) transplants (Kottaridis et al, 2000; Chakraverty et al,
2002). Subsequent studies have reported lower rates of
chronic GVHD with equivalent overall survival compared
with GVHD prophylaxis with methotrexate or mycopheno-
late mofetil (Perez-Simon et al, 2002; Delgado et al, 2008;
van Besien et al, 2009; Malladi et al, 2009). This is achieved,
however, at the expense of delayed immune reconstitution
(Morris et al, 2003; Dodero et al, 2005), an increase in
opportunistic infections (Chakrabarti et al, 2002a,b; Perez-
Simon et al, 2002; Avivi et al, 2004) and higher incidence of
mixed chimerism, which may impair graft-versus-leukaemia
responses (Mackinnon et al, 1994).
The risks of T cell depletion can be ameliorated by donor
lymphocyte infusions (DLIs) (Peggs et al, 2004, 2007; Bloor
et al, 2008; Thomson et al, 2010; Mohamedbhai et al, 2012;
Liga et al, 2013) but there is a need to define minimum
levels of T cell depletion that provide effective protection
from GVHD in different settings. A formal dose de-escala-
tion study in MRD transplants concluded that a single
alemtuzumab dose of 30 mg on day 1 is sufficient to
prevent GVHD (Chakraverty et al, 2010) but equivalent
studies in MUD transplants are lacking. Favourable outcomes
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have been reported in mixed cohorts of MRD and MUD
transplants for a wide range of alemtuzumab doses from
50 mg to as little as 10 mg (Faulkner et al, 2004; Khouri
et al, 2004; Tholouli et al, 2008; Bertz et al, 2009; Spyridoni-
dis et al, 2011; Gartner et al, 2013; Potter et al, 2014). These
are difficult to interpret: first, they involve mixed cohorts of
MRD and MUD transplants; and second, the definition of
‘adequate’ control of GHVD is entirely subjective with some
centres tolerating much higher rates of acute GVHD and
extensive chronic GVHD than others.
In the absence of a formal de-escalation study in MUD
transplants and lack of rational criteria to define adequate
GVHD prophylaxis, we compared an empirically reduced
dose of 60 mg alemtuzumab in MUD transplants, with
30 mg for MRD transplants, previously defined by formal
study (Chakraverty et al, 2010). This offers an objective
assessment of the potential of alemtuzumab to modify unre-
lated donor alloreactivity, relative to the level of a sibling
donor.
Methods
Study design and ethics
The study included sequential patients transplanted with FM
conditioning, following the introduction of de-escalated ale-
mtuzumab dosing for MRD and MUD transplants in 2006.
Clinical records were interrogated for GVHD, survival, chi-
merism testing and ciclosporin levels. All patients gave con-
sent for clinical follow-up and post-transplant serum
sampling for research purposes, according to protocols
approved by the local research ethics committee of North-
umberland and North Tyneside.
Conditioning regimen and alemtuzumab dosing
All patients received fludarabine 30 mg/m2 per day from day
7 to 3 and melphalan 140 mg/m2 day 2. Alemtuzumab
30 mg was given on day 2 for MRD transplants and on
days 4 and 2 for MRD transplants (total 60 mg). Day 2
was preferred rather than day 1 because kinetic studies
indicated a steep decline in levels in the first 24 h after infu-
sion (Morris et al, 2003). We reasoned that the timing of
stem cell infusion, which is not well controlled, would have
less effect on the level of T cell depletion if we allowed 48 h
following alemtuzumab adminstration, at which point ale-
mtuzumab levels would be more stable. A minimum CD34+
stem cell dose of 4 9 106/kg was infused in all patients. His-
torical patients treated with 100 mg of alemtuzumab received
20 mg daily from day 7 to 3, inclusive.
Post-transplant monitoring and management
Graft-versus-host disease prophylaxis was ciclosporin given at
25 mg/kg twice daily from day 1 (with a target of 200–
300 lg/l). Ciclosporin levels were monitored twice weekly by
enzyme-linked immunosorbent assay. Tapering began at day
+30 in the absence of GVHD. All patients received chemo-
prophylaxis against Pneumocystis jirovecii and Varicella Zos-
ter. Serum cytomegalovirus (CMV) copy number was
assessed twice weekly by polymerase chain reaction (PCR)
and pre-emptive therapy was initiated if copy number rose
above >104. Peripheral blood and bone marrow chimerism
was tested by short tandem repeat PCR on unfractionated
bone marrow and magnetically-selected CD3+ and CD15+
fractions of peripheral blood. Monitoring took place monthly
until day +100 and 3-monthly thereafter. A schedule of DLIs,
escalating by half-log increments every 3 months was insti-
tuted for persistent partial chimerism, beginning at 3 9 105/kg
at 6 months. Patients with early relapse received 10-fold
higher doses at 4–6 weekly intervals. Clinical assessment of
acute GVHD was performed at least once weekly in the first
100 d using modified Glucksberg criteria (Hunt et al, 2001).
Incidence of chronic GVHD was assessed at 1 year post-
transplant and graded using both Seattle and National Insti-
tutes of Health criteria (Shulman et al, 1980; Filipovich et al,
2005). Body surface area was estimated by the method of
Dubois (Dubois & Dubois, 1916).
Serum alemtuzumab measurement
Post-transplant serum samples were available from 20
MRD recipients and 13 MUD recipients at day +1 and 11
MRD recipients and nine MUD recipients at day 3–4.
Alemtuzumab concentration was measured as previously
described by a validated flow cytometry assay (Rebello &
Hale, 2002).
Statistical methods
Intergroup analyses were performed with Student’s t test for
continuous variables, Mann–Whitney test for proportions
and Chi-square for contingency. The three group-compari-
son of serum alemtuzumab levels used one-way analysis of
variance (ANOVA). Multiple t-tests used for intergroup analy-
sis of serum ciclosporin levels over time were subjected to
sequential Bonferroni correction. Overall survival was analy-
sed by the Kaplan Meier method with log–rank test to
compare survival curves. Relapse and non-relapse mortality
were analysed by the cumulative incidence method with
relapse as a competing event for non-relapse mortality
(NRM) and vice-versa. Cumulative incidence curves were
compared with Gray’s test. Hazard ratios were calculated by
Cox Regression modelling. Graphing and statistical analyses
were performed with GRAPHPAD PRISM version 6.0 (GraphPad
Software, Inc. La Jolla, CA, USA) except for cumulative
incidence, which was performed with R version 3.1.0 and
Cox Regression, which was performed with SPSS version 21
(IBM United Kingdom Ltd., Portsmouth, UK). P < 005
was recorded as significant.
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Results
Patient characteristics
From May 2006 to May 2009, 24 patients received MRD
transplants and 19 received MUD transplants. Over this per-
iod a total of 51 patients were transplanted with reduced
intensity conditioning (Fig 1). Eight were not included in the
study because they were transplanted with different doses of
alemtuzumab (two MRD and two MUD transplants) or the
MUD transplants were less than 9/10 human leucocyte anti-
gen (HLA)-matched (four patients). Patients included in the
study were well matched for age, transplant indication and
donor/recipient CMV status (Table I). All MRD recipients
were 12/12 HLA-matched. Seventeen of the unrelated
donors were 10/10 matched at high resolution. Two donors
were 9/10 matched due to single allele mismatches in
HLA-Cw.
Serum Alemtuzumab levels
Serum had been collected on days +1, +3–4 and +7 for im-
munomonitoring and a selection of samples was available for
measurement of alemtuzumab levels. On day +1, the
mean  standard deviation (SD) serum alemtuzumab level
was 29  11 lg/ml in MRD transplants (30 mg) compared
with 54  22 lg/ml in MUD transplants (60 mg);
(P = 00002; Fig 2A). A collection of samples taken on day
+3–4 was also available to compare dose-reduced transplants
with historical patients receiving 100 mg alemtuzumab
(Fig 2B). The serum alemtuzumab levels for both MRD
and MUD transplants were significantly lower with
mean  SD of 23  08 and 43  18 lg/ml, respectively,
compared with 82  60 lg/ml for recipients of 100 mg of
alemtuzumab (P < 00028). Alemtuzumab dosing regimens
in adults do not usually take into account the size of the
patient but an inverse relationship was observed between
alemtuzumab level and body surface area (BSA) in both
cohorts, reaching significance in MRD transplants (r2 = 070;
P < 00001; Fig 2C,D).
Chimerism
Chimerism data were available for all (n = 39) patients
evaluable at day +100. Median myeloid engraftment (CD15+
cells) was 100% in both cohorts (not shown). Donor T cell
engraftment (CD3+ cells) was significantly higher in MUD
than MRD recipients (median  interquartile range:
88  33 compared with 21  46; P = 00002; Fig 3A). As a
result of treating partial T cell chimerism pre-emptively in
patients surviving more than 6 months, fewer MUD patients
received DLI (4/19; seven doses in total) compared with
MRD patients (20/24; 31 doses in total), P < 00001.
Graft-versus-host disease
Overall, 13 out of 16 (81%) MUD recipients surviving to day
+100 experienced acute GVHD compared with 1 out of 23
(4%) MRD recipients, P < 00001. GVHD grade II or greater
occurred only in MUD recipients (44% vs. 0%, P < 00001)
(Fig 3B). Similarly, chronic GVHD was more common in
MUD recipients (55% vs. 20%; P < 00001) and more often
extensive (Fig 3C).
Table I. Patient characteristics.
Patient baseline data
FMA 30
n = 24
FMA 60
n = 19 P
Age at transplant (years), mean  SEM 45  13 48  29 ns
Gender direction of transplant n (%)
Male to male 8 (33) 10 (53) ns
Male to female 6 (25) 6 (32)
Female to male 7 (29) 1 (5)
Female to female 3 (13) 2 (11)
Transplant indication
AML 14 (58) 9 (47) ns
MDS 2 (8) 1 (5)
NHL 6 (25) 2 (11)
HL 1 (4) 3 (16)
CML 1 (4) 0
Myeloma 0 3 (16)
Other 0 1 (5)
Stem cell source
PBSC 18 (75) 15 (79) ns
BM 6 (25) 4 (21)
CMV (donor/recipient)
Negative/positive 10 (42) 5 (26) ns
Positive/positive 5 (21) 6 (32)
Positive/negative 2 (8) 2 (11)
Negative/negative 5 (21) 6 (32)
FMA, fludarabine, melaphalan, alemtuzumab; SEM, standard error
of the mean; AML, acute myeloid leukaemia; MDS, myelodysplastic
syndrome; HNL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma;
CML, chronic myeloid leukaemia; PBSC. Peripheral blood stem cells;
BM, bone marrow; CMV, cytomegalovirus.
Total allografts: 82 
Reduced intensity: 51 Myeloablative: 24 FLAMSA: 3 
Aplastic anaemia: 3 
Cord: 1 
MMUD FMA90: 4 
(excluded) 
Sibling FMA30: 24 
(excluded FMA20: 2) 
MUD FMA60: 19 
(excluded: FMA30: 2) 
Fig 1. Consort diagram summarising patients included in the study.
FMA: fludarabine, melphalan, alemtuzumab (dose in mg); FLAMSA:
fludarabine, cytarabine, amsacrine (with cyclophosphamide and total
body irradiation transplant); MUD, matched unrelated donor;
MMUD, mismatched unrelated donor (<9/10 antigen-mismatched
MUD).
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Immunosuppression
Ciclosporin was tapered in the absence of GVHD from day
+30. Increased GVHD in the MUD recipients was reflected
by diverging mean serum ciclosporin concentrations from
day +50 (Fig 4A). Overall, 13/16 (81%) MUD recipients still
received ciclosporin at day +100 compared with 5/23 (22%)
MRD recipients. Ciclosporin was completely withdrawn from
all MRD recipients by day 128 but 7/16 (44%) MUD recipi-
ents still required immunosuppression.
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Fig 2. (A) Comparison of mean serum ale-
mtuzumab level on day +1 in matched related
donor (MRD) recipients of 30 mg and
matched unrelated donor (MUD) recipients of
60 mg **P = 00002. (B) Comparison of mean
serum alemtuzumab level on day +3–4 in
MRD recipients of 30 mg, MUD recipients of
60 mg and historical controls receiving 100 mg
alemtuzumab **P = 00028. (C) Correlation
between body surface area and serum ale-
mtuzumab in MRD recipients of 30 mg; open
symbols indicate bone marrow (BM); closed
symbols indicate peripheral blood stem cell
(PBSC) grafts. (D) Correlation between body
surface area (Dubois) and serum alemtuzumab
in MUD recipients of 60 mg. Open symbols
indicate BM; closed symbols indicate PBSC
grafts.
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blood T cell chimerism at day 100 in matched
unrelated donor (MRD) recipients of 30 mg
and matched unrelated donor (MUD) recipi-
ents of 60 mg alemtuzumab **P = 00002. (B)
Incidence and severity of acute graft-versus-
host disease (GVHD) in MRD recipients of
30 mg and MUD recipients of 60 mg ale-
mtuzumab; **P < 00001. (C) Incidence and
severity of chronic GVHD in MRD recipients
of 30 mg and MUD recipients of 60 mg ale-
mtuzumab; **P < 00001.
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Cytomegalovirus reactivation
Cytomegalovirus reactivation was seen in 15 (35%) patients
overall. The reactivation rates in CMV seropositive individu-
als were 69% in MUD recipients and 35% in MRD recipi-
ents, P < 00001 (Fig 4B).
Relapse mortality, non-relapse mortality and overall
survival
Estimates for cumulative incidence of non-relapse mortality
at day +100 and 2 years were 4% (95% confidence interval
[CI] 2–19%) and 17% (5–35%) for MRD recipients and 15%
(4–34%) and 20% (6–40%) for MUD recipients (Fig 5A).
The hazard ratio for NRM in MUD versus MRD recipients
was 1337 (95% CI 0333–5370), P = 0682. Cumulative
incidence of relapse at 2 years was 28% (11–50%) in MRD
recipients and 35% (10–62%) in MUD recipients (Fig 5B).
The hazard ratio for relapse in MUD versus MRD recipients
was 1116 (95% CI 0353–3527), P = 0857. By Kaplan–Me-
ier analysis, the median survival was 804 d in MRD and 609
in MUD transplant recipients. Overall survival proportions at
2 years were 54% (31–72%) and 45% (18–69%) in MRD
and MUD recipients, respectively (Fig 5C). The hazard ratio
for death in MUD versus MRD recipients was 1135 (95% CI
0455–2831), P = 0785.
Discussion
The optimal dose of alemtuzumab for in vivo T cell depletion
of reduced intensity conditioned transplantation is contro-
versial and depends upon subjective judgments about the
level of GVHD that tolerable or desirable, the perceived risk
of relapse and the willingness of physicians to use pre-emp-
tive DLI to bolster post-transplant immune reconstitution.
The overall survival has been reported to be comparable
between patients receiving widely ranging levels of in vivo
T cell depletion (Perez-Simon et al, 2002; Delgado et al,
2008; van Besien et al, 2009; Malladi et al, 2009). The use of
alemtuzumab is generally associated with higher relapse risk
but less non-relapse death and proponents argue that the
quality of survivorship is improved by the prevention of
extensive chronic GVHD (Perez-Simon et al, 2002), particu-
larly in the T cell compartment.
Here we have evaluated 60 mg dosing for MUD trans-
plants relative to the 30 mg dose, defined as optimal for
stringent control of GVHD in MRD transplants (Chakraverty
et al, 2010). Monitoring of serum indicates that much lower
levels are achieved than with 100 mg of alemtuzumab and
that there is a predictable difference between 30 mg for
MRD and 60 mg for MUD transplants, at day +1. We
elected to give alemtuzumab 1 d earlier than Chakraverty
et al (2010), at day 2, and the dose measured at day +1
was 30–40% lower than that reported on day 0 by these
authors (29 lg/ml for 30 mg and 54 lg/ml for 60 mg in
this study compared with approximately 5 and 75 lg/ml,
respectively). However, this did not appear to increase the
incidence of acute GVHD grades II–IV in our MRD cohort
(both studies <5%). We also demonstrated a significant
inverse relationship with BSA for MRD transplants and a
trend in the same direction for MUD transplants. Metre-
squared dosing is common in paediatric practise (Dodero
et al, 2005; Shah et al, 2007) and it is possible that more pre-
dictable outcomes would be observed if a similar approach
was taken in adults (Morris et al, 2003; Chakraverty et al,
2010). The use of one 30 mg dose (two 30 mg doses for
MUD transplants) in our schedule also makes economic
sense, as 30 mg is the presentation vial size of the drug. One
possible drawback is that the infusional toxicity of ale-
mtuzumab may be higher with a single dose than with sev-
eral fractionated doses, although we did not observe major
difficulties with this. Prior commencement of fludarabine
(day 7) before the first dose of alemtuzumab (day 4) may
have reduced the incidence of infusional toxicity in these
patients.
Our study is limited by the retrospective nature and
relatively small number of patients transplanted over the
period of observation. A prospective study would have been
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preferred but reduced alemtuzumab dosing in MUD trans-
plants was already common practise, making a large prospec-
tive study, similar to that performed in MRD transplants,
difficult to conduct. Comparison with the sibling cohort
receiving 30 mg of alemtuzumab, rather than the historical
MUD cohort receiving 100 mg, was motivated by the fact
that sibling 30 mg and MUD 60 mg could be compared con-
temporaneously and that the most carefully annotated dose
regime in the literature is the 30 mg dose given to siblings.
The power of the study to detect differences in survival is
rather low as indicated by wide confidence intervals in the
hazard ratios. However, our primary aim was to report out-
comes related to the control of GVHD. The observation that
overall survival remains relatively constant with different lev-
els of GVHD prophylaxis has been reported in several other
studies (Perez-Simon et al, 2002; Delgado et al, 2008; van
Besien et al, 2009; Malladi et al, 2009).
Mixed cohorts of MRD and MUD transplant patients
treated with lower doses of alemtuzumab have satisfactory
outcomes overall (Faulkner et al, 2004; Khouri et al, 2004;
Tholouli et al, 2008; Bertz et al, 2009; Spyridonidis et al,
2011; Gartner et al, 2013; Potter et al, 2014). In a large series
of 58 MRD and 69 MUD transplants subjected to a reducing
regimen of 40, 20 and 10 mg of alemtuzumab, it was possi-
ble to infer differences between the response of MRD and
MUD patients to alemtuzumab (Bertz et al, 2009). For exam-
ple, MUD transplants receiving 40 mg experienced 27%
grade II–IV GVHD compared with MRD patients receiving
10 mg who only experienced 10% grade II–IV. This suggests
that unrelated donors cause significantly more alloreactivity
in this range of alemtuzumab dosing. In support of this, we
found that 44% of MUD transplants experienced grade II–IV
acute GVHD after 60 mg of alemtuzumab compared with
0% of MRD patients after 30 mg of alemtuzumab. Both
reports are consistent in finding more acute and chronic
GVHD with MUD transplants, even when alemtuzumab dos-
ing was increased by several fold.
In keeping with higher rates of GVHD, we observed
higher donor T cell chimerism at day 100 in MUD trans-
plants and recorded lower use of DLI compared with MRD
transplants managed with the same pre-emptive DLI policy.
Higher indices of alloreactivity in MUD transplants were not
due to more aggressive withdrawal of immunosuppression,
as higher ciclosporin levels were maintained in these patients
after day 50. Survival, relapse and non-relapse outcomes were
comparable as in other studies. One limitation of this report
is that we did not record quality of life, which may have
been relatively impaired in MUD transplants owing to a
higher rate of extensive chronic GVHD.
Our data suggest that 60 mg of alemtuzumab does not
achieve equivalent control of GVHD compared with 30 mg
in MRD transplants. However, it may be na€ıve to assume
that an ‘equivalent’ dose can be reached by simple titration.
Review of MUD transplant patients receiving the original
100 mg dose indicates a 20% incidence of acute GVHD
grades II–IV (Mead et al, 2010). Notably, this level of acute
GVHD is still above that reported for MRD transplants with
30 mg dose (0–5%) and only marginally increases to 22%
when mismatching is permitted in unrelated donors (Mead
et al, 2010). These observations suggest that the relationship
between alemtuzumab dose and antigenic disparity is non-
linear and that it may not be possible to achieve equivalent
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GVHD prophylaxis between MUD and MRD transplants
simply by dose adjustment. Fortunately, as many studies
illustrate, overall survival often remains stable despite signifi-
cant variation in the burden of GVHD (Perez-Simon et al,
2002; Delgado et al, 2008; van Besien et al, 2009; Malladi
et al, 2009). Further improvements in outcome may yet be
achievable by paying close attention to individualised dosing
of alemtuzumab based on BSA, expression of CD52 by
malignant cells and the risk of graft rejection or relapse
(Khouri et al, 2004; Chakraverty et al, 2010; Mead et al,
2010). Attention to long-term quality of life measurements is
also paramount.
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